Company is advancing RE104, its proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy to provide lasting benefits to patients with ...
Reunion Neuroscience, a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk Foundation’s investment arm Novo Holdings. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results